For six years, Thomas thought he’d beaten it.
The depression that had consumed his late twenties—the year he couldn’t leave his apartment, the medication adjustments, the intensive outpatient program, the slow climb back to a life that felt worth living—all of it had eventually resolved into something he could only describe as normal. He tapered off sertraline under his psychiatrist’s guidance. He moved to San Luis Obispo for a fresh start, got a job managing a craft brewery, started mountain biking, fell in love. The depression became something he referenced in past tense, like a bad roommate who’d finally moved out.
Then, at forty-three, it came back.
Not in a dramatic collapse. Not triggered by anything he could identify. Just a slow, creeping return of the heaviness—the same heaviness he’d spent years learning to recognize, and more years believing he’d left behind for good. The alarm clock felt heavier. Conversations required more effort. The trails he loved looked the same but felt flat, as though someone had quietly removed the third dimension from the landscape.
The worst part wasn’t the symptoms themselves. He knew depression. He’d survived it before. The worst part was the specific devastation of losing something he thought he’d earned permanently. The worst part was the thought: I did everything right. I did the therapy, the medication, the lifestyle changes. And it still came back. What’s the point of fighting it if it just comes back?
If you’re reading this because your depression has returned after months or years of remission, this article is for you. Not to minimize what you’re experiencing. Not to offer empty reassurance. But to explain why relapse happens, why it doesn’t mean treatment failed, and why the options available to you now are significantly different from what existed the last time you went through this.
Why Depression Comes Back
Depression relapse is not a failure of willpower, character, or previous treatment. It’s a neurobiological reality rooted in how the brain processes and encodes depressive episodes.
Research from the landmark STAR*D trial and subsequent longitudinal studies has established that depression is, for the majority of people who experience it, a recurrent condition. Approximately 50% of individuals who recover from a first depressive episode will experience at least one more. After two episodes, the recurrence rate climbs to roughly 70%. After three, it exceeds 90% (Burcusa & Iacono, 2007). These aren’t statistics about treatment failure—they’re statistics about the nature of the illness itself.
The mechanism behind this recurrence is a concept neuroscientists call “kindling.” First proposed by researcher Robert Post, the kindling hypothesis suggests that each depressive episode changes the brain in ways that make future episodes more likely and easier to trigger. Early episodes are often precipitated by identifiable stressors—a job loss, a breakup, a death. But with each recurrence, the threshold for triggering a new episode lowers. Eventually, depressive episodes can emerge with minimal or no identifiable precipitant, as though the brain has learned the pathway to depression so thoroughly that it can find its way there without a map (Monroe & Harkness, 2005).
At the neurobiological level, each depressive episode leaves its mark. Synaptic connections weaken. BDNF levels drop. The default mode network—the brain’s self-referential processing system, responsible for rumination and internal narrative—becomes more easily activated. Stress response systems become sensitized, producing larger cortisol responses to smaller triggers. The brain, in essence, becomes more efficient at producing depression with each episode it survives.
This isn’t a hopeless finding. Understanding kindling actually points toward more effective treatment strategies. If the core problem is that depressive episodes leave structural and functional damage that predisposes the brain to future episodes, then the most effective intervention isn’t just treating the current episode—it’s restoring the brain’s neuroplasticity and resilience so that future episodes are less likely to take hold.
Why This Time Feels Different (and Harder)
People experiencing depression relapse after extended remission frequently describe it as qualitatively different from the first time—and often, in specific ways, harder. Understanding why can help normalize what you’re feeling and guide treatment decisions.
The grief of loss. A first depressive episode, however devastating, doesn’t carry the additional weight of lost progress. A relapse does. You’re not just dealing with depression—you’re dealing with depression plus the grief of having had something good and losing it. You’d built a life you were proud of. You’d made plans that assumed continued wellness. The relapse threatens not just your current mood but your faith in the durability of recovery itself.
The trust deficit. After a relapse, it’s profoundly difficult to trust that treatment will work again—or, if it does work, that the results will last. This trust deficit can delay treatment-seeking and undermine engagement with treatment once it begins. The internal logic is understandable: Why invest in recovery if I’m just going to lose it again? This thought, while natural, is itself a symptom of depression—a cognitive distortion that masquerades as rational analysis.
The identity disruption. For Thomas, six years of wellness had become part of his identity. He was someone who had overcome depression. The relapse didn’t just change how he felt—it changed how he understood himself. If depression is something you can overcome, relapse means you failed. If depression is something you manage, relapse is an expected part of the process. The shift from the first framework to the second is emotionally necessary but genuinely painful.
The medication question. Many people who relapse after remission had, at some point, discontinued their antidepressant medication—sometimes under medical guidance, sometimes on their own. The relapse can trigger intense guilt about this decision, even when discontinuation was clinically appropriate at the time. It’s important to understand that while maintenance medication reduces relapse risk, it doesn’t eliminate it. People relapse on medication too. The decision to taper was not necessarily the cause of your relapse, and self-blame about that decision is neither accurate nor productive.
What’s Changed Since Your Last Episode
If your previous treatment for depression involved SSRIs, therapy, or both, you should know that the treatment landscape has expanded significantly. The most important development is the emergence of ketamine-based therapies, which work through an entirely different mechanism than any antidepressant you’ve taken before.
Traditional antidepressants modulate serotonin and norepinephrine—neurotransmitters that play a role in mood but don’t directly address the structural brain changes that depression causes and that kindling perpetuates. They can be effective, and for many people they remain an important part of treatment. But their limitations are well-documented: delayed onset of action (four to six weeks), incomplete response in roughly one-third of patients, and a mechanism that treats symptoms without directly repairing the neuroplastic damage underlying the condition.
Ketamine therapy works through the glutamate system—the brain’s most abundant neurotransmitter network—rather than the serotonin system. When administered at subanesthetic doses, ketamine triggers a cascade of neurobiological events: NMDA receptor blockade leads to increased glutamate release, which activates AMPA receptors, stimulates BDNF production, and promotes rapid synaptogenesis—the formation of new synaptic connections in mood-regulating brain regions (Duman et al., 2016).
For relapse patients specifically, this mechanism has a particularly relevant implication. Ketamine doesn’t just improve mood. It promotes the structural repair of neural circuits that previous depressive episodes have damaged and that kindling has made vulnerable. It addresses the accumulated neurobiological toll of recurrent depression in a way that serotonin-based medications cannot.
The speed of response is also critically important for relapse patients. When you’ve been through depression before, you know what’s coming. You can feel the trajectory. The prospect of waiting four to six weeks for an SSRI to potentially begin working—while the depression deepens and your functional capacity erodes—is significantly more daunting the second or third time around. Ketamine’s ability to produce meaningful symptom improvement within hours to days can interrupt the downward trajectory before it gains momentum.
Treatment Options at Innerbloom
At Innerbloom Ketamine Therapy, Dr. Ray Rivas evaluates each relapse patient’s complete history—including prior episodes, previous treatment responses, current medication status, and co-occurring conditions—before recommending a treatment pathway.
IV Ketamine. Administered intravenously at 0.5 mg/kg over 40 minutes, IV ketamine offers the highest bioavailability (approximately 100%) and the most precise dose control. The standard induction involves six treatments over two to three weeks, with response rates of 70–80% in treatment-resistant populations. Innerbloom’s data show an 82% therapeutic response rate with their comprehensive protocol. For relapse patients who want the most rapid and potent intervention, IV ketamine is often the first recommendation.
IM Ketamine. Intramuscular ketamine delivers approximately 93% bioavailability through a single injection, avoiding IV placement. It’s an effective option for patients who prefer a less invasive delivery method while maintaining high therapeutic potency.
SPRAVATO® (esketamine). For patients whose relapse meets criteria for treatment-resistant depression—defined as inadequate response to at least two antidepressant trials—SPRAVATO® offers an FDA-approved, insurance-covered pathway to glutamate-based treatment. Administered as a nasal spray with a two-hour monitoring period, SPRAVATO®follows a structured schedule: twice weekly for four weeks, then weekly, then every one to two weeks for maintenance. In January 2025, the FDA expanded SPRAVATO®’s approval to include standalone use without a concurrent oral antidepressant.
For relapse patients navigating the financial and emotional burden of starting treatment again, SPRAVATO®’s insurance coverage can remove a significant barrier. The knowledge that this treatment is FDA-approved for exactly your situation—depression that hasn’t responded to conventional antidepressants—can also provide a degree of reassurance that matters during a vulnerable time.
Ketamine-Assisted Psychotherapy (KAP). Relapse carries a psychological burden beyond the depressive symptoms themselves. The grief, the self-blame, the damaged trust in recovery, the fear of it happening again—these layers require therapeutic attention that medication alone, even rapidly effective medication, can’t fully address. KAP with certified therapist Cindy Nelson, LMFT, uses the neuroplastic window ketamine creates to facilitate deeper therapeutic processing. For relapse patients, this work often focuses on reframing the relapse narrative, developing a maintenance identity (managing a chronic condition rather than “beating” an episode), and building resilience strategies that reduce vulnerability to future episodes.
Building a Relapse-Resilient Recovery
Recovery from a relapse is not just about resolving the current episode. It’s about building a framework that reduces the probability and impact of future recurrences. At Innerbloom, this framework includes several components that extend well beyond the treatment chair.
Maintenance treatment planning. Unlike the first time you recovered—when you may have assumed that remission meant permanent cure—this recovery should include a clear, proactive maintenance plan. For many patients, this means scheduled booster treatments at intervals determined by their individual response. Some patients maintain well with a single ketamine booster every two to three months. Others benefit from ongoing SPRAVATO maintenance sessions. Dr. Rivas works with each patient to develop a maintenance cadence that balances effectiveness, convenience, and cost.
Early warning system development. Your previous experience with depression gives you a significant advantage: you know your early warning signs. Working with your treatment team, you can develop a personalized early intervention protocol—specific, concrete steps to take when you notice the first signs of symptom return, before a full episode develops. This might include scheduling an additional booster session, increasing therapy frequency, or activating specific behavioral strategies.
Integration with existing providers. Innerbloom collaborates with each patient’s existing mental health providers—psychiatrists, therapists, primary care physicians—to ensure continuity of care. Relapse treatment doesn’t replace your existing treatment relationships; it augments them with a tool that addresses the neuroplastic dimension of recurrent depression.
Lifestyle integration. The neuroplastic changes ketamine promotes are most durable when reinforced by practices that support brain health: regular physical activity, adequate sleep, social connection, stress management, and continued therapeutic engagement. These aren’t replacements for treatment—they’re amplifiers of it.
What Thomas Found
Thomas started IV ketamine at Innerbloom eight weeks after recognizing his relapse. He’d spent six of those weeks trying to convince himself it would pass on its own—a delay he now describes as a form of depression-driven denial.
After his second infusion, his wife told him his eyes looked different. “You’re in there again,” she said. He wasn’t sure what she meant until the next morning, when he drove to work along the same route he always took and noticed that the hills were green. They’d been green for weeks—it was February on the Central Coast. He just hadn’t been seeing it.
Thomas now maintains his remission with a booster infusion every eight to ten weeks, adjusted seasonally based on his symptom patterns. He continues therapy. He takes his monitoring seriously—checking in with himself, with his wife, and with his treatment team at regular intervals.
The difference between this recovery and his first one is the framework. He no longer thinks of depression as something he defeated. He thinks of it as something he manages—with tools that are faster, more targeted, and more effective than anything he had access to the first time around. The relapse didn’t mean his original recovery was a failure. It meant his condition needed a different, more sophisticated level of ongoing support.
And that support exists now in a way it didn’t before.
Key Takeaways
- Depression relapse after remission is neurobiologically expected, not a personal failure. The “kindling” effect means each depressive episode lowers the threshold for future episodes, with recurrence rates reaching 70–90% after two or more prior episodes.
- Relapse carries unique psychological burdens beyond the depressive symptoms themselves—including grief over lost progress, damaged trust in recovery, and identity disruption—that require specific therapeutic attention.
- Ketamine and SPRAVATO® address the structural brain damage that recurrent depression causes and that makes future relapse more likely, targeting neuroplasticity directly rather than modulating serotonin indirectly.
- SPRAVATO® is FDA-approved and often insurance-covered for treatment-resistant depression, including its expanded 2025 monotherapy indication, providing an accessible pathway for patients navigating the financial burden of re-entering treatment.
- Relapse-resilient recovery requires a maintenance framework, including scheduled booster treatments, early warning systems, integration with existing providers, and lifestyle practices that reinforce neuroplastic gains—transforming recovery from a one-time achievement into an ongoing, sustainable practice.
About the Author
Dr. Rivas is a ketamine specialist and board-certified acute care and trauma surgeon with over 12 years of experience in ketamine administration. Before founding Innerbloom Ketamine Therapy in 2022, Dr. Rivas served on the frontlines of emergency and trauma medicine in Santa Maria, CA, and Austin, TX. Dr. Rivas applies his extensive medical expertise to provide safe, evidence-based ketamine treatments for mood disorders, including depression, anxiety, PTSD, and chronic pain. His passion lies in helping patients find relief and rediscover hope through personalized, compassionate care.
Newy: Bridging the Gap Between Ketamine Treatment and Everyday Wellness
A supplement formulated by Dr. Rivas for enhanced brain and mood support. The formula pairs especially well with ketamine therapy by helping extend and enhance the neuroplasticity effects. That said, the ingredients are equally effective on their own, so it’s a supportive option whether or not someone is undergoing ketamine treatment. Learn more about how Newy supports cognitive function detoxification and cellular repair.
References
Burcusa, S. L., & Iacono, W. G. (2007). Risk for recurrence in depression. Clinical Psychology Review, 27(8), 959–985. https://pubmed.ncbi.nlm.nih.gov/17448579/
Monroe, S. M., & Harkness, K. L. (2005). Life stress, the “kindling” hypothesis, and the recurrence of depression: Considerations from a life stress perspective. Psychological Review, 112(2), 417–445. https://pubmed.ncbi.nlm.nih.gov/15783292/
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016). Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nature Medicine, 22(3), 238–249. https://pubmed.ncbi.nlm.nih.gov/26937618/
Bockting, C. L. H., Hollon, S. D., Jarrett, R. B., Kuyken, W., & Dobson, K. (2015). A lifetime approach to major depressive disorder: The contributions of psychological interventions in preventing relapse and recurrence. Clinical Psychology Review, 41, 16–26. https://pubmed.ncbi.nlm.nih.gov/25754289/
Phillips, J. L., Norris, S., Talbot, J., et al. (2019). Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: A randomized controlled trial. American Journal of Psychiatry, 176(5), 401–409. https://pubmed.ncbi.nlm.nih.gov/30922101/
Medical Disclaimer
All content on this website, including but not limited to this article, blog posts, testimonials, and FAQs, is not medical advice and should not be considered as such. This website cannot diagnose or treat any medical condition. Only a licensed medical professional who is familiar with you and your medical history can provide medical advice, diagnosis, or treatment.
The information provided here is for educational and informational purposes only. It is not intended to replace a consultation with a qualified healthcare provider. If you are experiencing symptoms of depression or any mental health condition, please consult with a licensed mental health professional or your primary care physician.
If you are in crisis or experiencing suicidal thoughts, please call the 988 Suicide and Crisis Lifeline (call or text 988) or go to your nearest emergency room immediately.
Innerbloom Ketamine Therapy cannot be held responsible or liable for any actions taken by those who access our website or rely on its content. Please refer to our Terms & Conditions for more information.
Depression came back, but you don’t have to fight it the same way. Contact Innerbloom Ketamine Therapy at (805) 592-5085 or visit us at 100 Casa Street, Suite D3, San Luis Obispo, CA 93405. We offer complimentary consultations to discuss how today’s treatment options can address what yesterday’s couldn’t.